OR WAIT 15 SECS
The poster references trials on EpiCor that have demonstrated the ingredient’s ability to function as an immune-modulating agent.
On April 11 at the Experimental Biology Conference in Washington, DC,Embria Health Sciences (Ankeny, IA) will present a scientific poster on its yeast-based fermentate ingredient EpiCor.
Titled “Yeast-Based Fermentate Supplementation Significantly Reduces Inflammation in Two Separate In Vivo Models,” the poster also references three published, double-blind, placebo-controlled randomized trials on EpiCor that have demonstrated the ingredient’s ability to function as an immune-modulating agent by significantly reducing common cold/flu-like and allergic rhinitis symptoms.
Related Content:Immune Support